Recursion Pharmaceuticals (RXRX) Stock Statistics & Valuation Metrics

Recursion Pharmaceuticals has a market cap or net worth of $1.80B. The enterprise value is $881.95M.

Recursion Pharmaceuticals has 514,190,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

Recursion Pharmaceuticals’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -48.06%.

The current PE Ratio of Recursion Pharmaceuticals is ―. Recursion Pharmaceuticals’s PEG ratio is 0.19.

In the last 12 months, Recursion Pharmaceuticals had revenue of 74.68M and earned -644.76M in profits. Earnings per share was -1.44.

In the last 12 months, operating cash flow was -371.81M and capital expenditures -6.47M, giving a free cash flow of -378.28M billion.

Recursion Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Recursion Pharmaceuticals upcoming earnings date is May 11, 2026, Before Open (Confirmed).

Recursion Pharmaceuticals as a current ratio of 5.50, with Debt / Equity ratio of 6.89%

In the past 12 months, Recursion Pharmaceuticals has paid -136.00K in taxes.

Recursion Pharmaceuticals EV to EBITDA ratio is -2.08, with an EV/FCF ratio of -3.08.

Recursion Pharmaceuticals has $743.29M in cash and marketable securities with $77.97M in debt, giving a net cash position of $665.33M billion.

Gross margin is -32.05%, with operating margin of -867.87%, and net profit margin of -863.35%.

The average price target for Recursion Pharmaceuticals is $8.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy